On the stock market since 2018, it operates in the world of health and science. It has 8,300 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 10% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $2.4B. In times of high interest rates, a gap like that can squeeze a company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly above the class average — a step short of the very top.
There is growth, but not at top-of-the-class tempo.
The stock has been running stronger than the market lately.
No real weak spot in any of the five subjects — a balanced report card.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades 35% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 11% a year on average.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
The average analyst price target is $18.67 — 58% above today’s price.
The company’s market value is 52 times its annual profit. Even a small disappointment could hit the price hard.
Costs swallow the gains that sales growth brings in. Council score: 4/10.
On our five-subject report card, AMRX sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: AMRX is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.